Special Issue

Antibacterial Topical Treatment - New Perspectives

Message from the Guest Editor

Inflammatory diseases of the skin and soft tissues represent a significant group of human infections. The most common cause is infection by Gram-positive *Staphylococcus aureus* bacteria Promising in this sense is treatment based on the antibacterial effect of enzymatic preparations (so-called enzybiotics), which degrade the bacterial cell wall. In addition to enzymes and peptides, researchers are also focusing on phage therapy, extracts of extracellular enzymes from various microorganisms, or skin probiotics. In addition to the development of standardization for testing the sensitivity of new substances for the needs of topical skin treatment, it is also necessary to standardize the animal skin model. This Special Issue will focus on information that may lead to more relevant and comparable results in preclinical development in the testing of antimicrobials for skin and soft tissue infections. Ultimately, the articles published in this Issue should contribute to the successful topical treatment of resistant bacterial infections. **Keywords:** antimicrobial therapy; emerging pathogens; bioactive compounds; skin model; local treatment; skin microbiome

Deadline for manuscript submissions

closed (30 June 2022)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/71982

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI